ByQuoth the Raven:
Amarin (AMRN) had fallen off of my radar.
After failing to convince the FDA to see things its way with regards to the ANCHOR indication for its sole drug, Vascepa, I pretty much stopped paying attention to the company. There...
Amarin (AMRN) has recently shown some modest improvement in Vascepa prescription numbers, reaching around 3,000 NRx per week again for the first time since October. This improvement comes despite Amarin cutting its salesforce...
NEW YORK (TheStreet) -- Let's open this week's Biotech Stock Mailbag with a question from Andy W.:
Is it possible that a Big Pharma might want to buy Amarin even more now so they could move to Ireland for the lower taxes?
"Inversion" -- the...
Amarin's lawyers were just in court last week suing the FDA for limiting the exclusivity it granted the drugmaker's fish oil pill Vascepa. But the Irish drugmaker hustled them back to court Tuesday, this time to sue AzstraZeneca, which is awaiting...
Q4 2013 Earnings Call
February 27, 2014 4:30 pm ET
John F. Thero - Chief Executive Officer, President, Principal Financial Officer, Principal Accounting Officer, Assistant Secretary and Director
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.